The AmoyDx EGFR Mutation Test Kit is a superior sensitive and selective assay for the detection of the most common somatic mutations in the Epidermal Growth Factor Receptor (EGFR) gene.

EGFR gene mutation relates to the drug response of Iressa (Gefitinib) and Tarceva (Erlotinib). The cancer patients with mutant EGFR genes are sensitive to Iressa and Tarceva, whereas the patients without EGFR mutations cannot be benefit from the treatments. However, the EGFR T790M mutation causes drug resistance. < XML:NAMESPACE PREFIX = O />

The Eurpean Drug Administration Organization requires the detection of EGFR gene mutation prior to the usage of Iressa on NSCLC patients. The NCCN 2009 recommended the usage of Tarceva on NSCLC patients with EGFR mutations. Two researches published on The New England Journal of Medicine states that the EGFR mutation detection should be operated prior to the employment of Iressa and Tarceva.